Company Overview
Company Type: Public Company
Website: genetether.com
Number of Employees: -
Ticker: GTTX (CNSX)
Year Founded: 2018


Business Description
GeneTether Therapeutics Inc., a genetic medicines company, focuses on developing gene editing therapies to enhance the efficiency of genome editing technologies. It is developing gene therapies for the treatment of patients with rare and monogenic kidney and skin diseases. The company was founded in 2018 and is based in Kelowna, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
2.0
Total Enterprise Value
0.1
EBIT
(1.6)
Cash & ST Invst.
2.0
P/Diluted EPS Before Extra
NM
Net Income
(1.5)
Total Debt
0.0
Price/Tang BV
0.9x
Total Assets
2.2
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Boivin, Roland 
Director & CEO
Garner, William James
Co-Founder & Executive Director
Sargent, R. Geoffrey
Co-Founder & Chief Scientific Officer
Jen, Jean M.
CFO & Corporate Secretary

Key Board Members
Name
Title
Graham, Daren N.
Chairman
Boivin, Roland 
Director & CEO
Garner, William James
Co-Founder & Executive Director
Jull, P. Gage
Independent Director
Neote, Kuldeep 
Chairperson of the Scientific Advisory Board
Figueiredo, Andre Pereira Fraga
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
301 – 1665 Ellis Street | Kelowna, BC | V1Y 2B3 | Canada
Phone: 514-796-2640   

Current and Pending Investors
KESA Partners, Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.04
Market Cap (mm)
2.0
Open
 0.04
Shares Out. (mm)
48.9
Previous Close
 0.04
Float %
17.3%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.04/ 0.04
Diluted EPS Excl. Extra Items
(0.04)
52 wk High/Low
 0.28/ 0.0050
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0030
Avg 3M Dly Vlm (mm)
0.07
Beta 5Y
-


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
GeneTether, Inc.
GeneTether, Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics and applications. It engages in building a discovery pipeline focused on the treatment of monogenic diseases of the kidney and the skin. The company is headquartered in San Francisco, California. GeneTether, Inc. operates as a subsidiary of GeneTether Therapeutics Inc.

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Mar-22-2022
Mar-29-2022
Private Placement
Target
GeneTether Therapeutics Inc. (CNSX:GTTX)


3.60
Nov-4-2021
Mar-29-2022
Public Offering
Target
GeneTether Therapeutics Inc. (CNSX:GTTX)


-
Feb-03-2021
Apr-14-2021
Private Placement
Target
GeneTether Therapeutics Inc. (CNSX:GTTX)


0.91
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-30-2023
End of Lock-Up Period
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.
Apr-11-2023
Annual General Meeting
GeneTether Therapeutics Inc., Annual General Meeting, Apr 11, 2023
Mar-30-2023
End of Lock-Up Period
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.
Sep-30-2022
End of Lock-Up Period
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2022.
Jun-07-2022
Company Conference Presentations
GeneTether Therapeutics Inc. Presents at LD Micro Invitational XII Conference, Jun-07-2022 03:30 PM


Advisors
Most Recent Auditor
Horne LLP
Private Placement Advisors
Research Capital Corporation
Public Offering Advisors
Horne LLP, Pushor Mitchell LLP


Most Recent Auditor
HORNE LLP


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Garner M.D., M.P.H., MPH, William James

21,738,919

44.45

0.6

Mar-10-2023


Sargent Ph.D., R. Geoffrey

11,196,974

22.90

0.3

Mar-10-2023


Figueiredo, Andre Pereira Fraga

2,563,061

5.24

0.1

Mar-10-2023


Graham Bba, Esq., J.D., Daren N.

2,431,508

4.97

0.1

Mar-10-2023


Ya, Zou 

2,239,394

4.58

0.1

Mar-10-2023


Jull B.Sc., C.F.A., M.B.A., P. Gage

148,919

0.30

0.0

Mar-10-2023


Boivin, Roland 

135,000

0.28

0.0

Sep-22-2023



 


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
COL4A5 (Future), COL7A1 (Future), PKD1 (Future), Precision Gene Editing Therapies (Future), SPINK5 (Future), UMOD (Future)


Upcoming Events
Date/Time
Type
Nov-24-2023
Estimated Earnings Release Date (S&P Global Derived)
Mar-30-2024
End of Lock-Up Period
Sep-30-2024
End of Lock-Up Period
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-25-2023
-
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
News Releases
189 KB
Aug-25-2023
Jun-30-2023
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
Interim Financial Statements
314 KB
May-25-2023
-
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
News Releases
219 KB
May-25-2023
Mar-31-2023
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
Interim Financial Statements
294 KB
May-01-2023
-
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
News Releases
180 KB
Apr-27-2023
-
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
News Releases
208 KB
Apr-27-2023
Dec-31-2022
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
Annual Financial Statements
106 KB
Apr-27-2023
Dec-31-2022
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
Annual Financial Statements
503 KB
Apr-27-2023
Dec-31-2022
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
Annual Financial Statements
56 KB
Mar-30-2023
-
GeneTether Therapeutics Inc. (CNSX:GTTX)
SEDAR
News Releases
223 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Boivin, Roland  (Director & CEO)
Oct-27-2022
Common Shares
5,000
911
Open Market Acquisition
3.85
Multiple
Boivin, Roland  (Director & CEO)
Oct-21-2022
Common Shares
1,500
329
Open Market Acquisition
1.17
Multiple
Boivin, Roland  (Director & CEO)
Oct-19-2022
Common Shares
5,000
992
Open Market Acquisition
4.05
Multiple
Garner M.D., M.P.H., MPH, William James (Co-Founder & Executive Director)
Oct-14-2022
Common Shares
5,000
1,233
Open Market Acquisition
0.02
Multiple
Graham Bba, Esq., J.D., Daren N. (Chairman)
Oct-14-2022
Common Shares
5,400
1,085
Open Market Acquisition
0.22
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Graham, Daren N.
Chairman
514-796-2640
-

Boivin, Roland 
Director & CEO
514-796-2640
-

Garner, William James
Co-Founder & Executive Director
514-796-2640
-

Jull, P. Gage
Independent Director
(416) 860-7614
-

Neote, Kuldeep 
Chairperson of the Scientific Advisory Board
514-796-2640
-

Figueiredo, Andre Pereira Fraga
Independent Director
514-796-2640
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Boivin, Roland 
Director & CEO
514-796-2640
-

Garner, William James
Co-Founder & Executive Director
514-796-2640
-

Sargent, R. Geoffrey
Co-Founder & Chief Scientific Officer
514-796-2640
-

Jen, Jean M.
CFO & Corporate Secretary
514-796-2640
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
